Clicky

Enlivex Therapeutics Ltd.(ENLV)

Description: Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.


Keywords: Medicine Clinical Medicine Immunology Solid Tumors Immune System Tumor Immunotherapy Cancer Treatment Virotherapy Coronavirus Cytokine Inflammatory Conditions Cytokine Release Syndrome

Home Page: www.enlivex.com

ENLV Technical Analysis

14 Einstein Street
Ness Ziona, 7403618
Israel
Phone: 972 8 662 3301


Officers

Name Title
Mr. Shai Novik M.B.A. Exec. Chairman
Dr. Oren Hershkovitz Ph.D. Chief Exec. Officer
Prof. Dror Mevorach M.D. Founder and Chief Scientific & Medical Officer
Ms. Shachar Shlosberger CPA Chief Financial Officer
Ms. Sigal Arad Director of HR
Mr. Veronique Amor-Baroukh Head Of CMC

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Information Technology
GIC Group: Software & Services
GIC Industry: Software
GIC Sub-Industry: Application Software
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.2047
Price-to-Sales TTM: 0
IPO Date: 1995-12-12
Fiscal Year End: December
Full Time Employees: 71
Back to stocks